NAC

N-acetylcysteine (NAC) is the N-acetylated derivative of the amino acid L-cysteine and a direct biosynthetic precursor to glutathione (GSH), the sulfhydryl tripeptide that serves as the principal antioxidant inside cells. It has been used clinically for decades, originally as a mucolytic that breaks the disulfide bonds cross-linking mucins to reduce mucus viscosity, and as the standard antidote for acetaminophen (paracetamol) poisoning, where it restores the hepatic glutathione pool depleted during drug detoxification ^[1].

As understanding of its mechanisms broadened, NAC's clinical applications expanded well beyond the lungs and liver. The discovery that it can modulate glutamate homeostasis, by stimulating the cystine-glutamate antiporter (system xc-) and thereby restraining excessive synaptic glutamate release, prompted extensive study in neuropsychiatric conditions characterized by impaired redox balance and glutamatergic tone ^[1][3]. Research programs have examined it across depression, anxiety, schizophrenia, bipolar disorder, obsessive-compulsive and addictive behaviors, chronic neuropathic pain, and neurodegenerative disease, as well as cardiovascular disease, contrast-induced nephropathy, and ophthalmology ^[1].

The clinical literature includes controlled trials. In schizophrenia, an eight-week randomized study using magnetic resonance spectroscopy found that NAC increased medial prefrontal glutathione and showed a trend toward reduced glutamate ^[3], and NAC has been proposed as a strategy to correct glutathione deficiency in the disorder. In multiple sclerosis, an eight-week randomized trial reported reductions in the lipid peroxidation marker malondialdehyde and improvement in anxiety symptoms ^[2]. Preclinical work links its antioxidant action to preservation of parvalbumin interneurons after early-life oxidative insults ^[6] and to facilitation of fear extinction by restoring glutathione homeostasis in the amygdala ^[5]. Reviews have also explored NAC in combination with acetyl-L-carnitine and citicoline for neurological and psychiatric indications ^[4].

NAC is widely available as an inexpensive oral supplement and pharmaceutical, sold in capsule, tablet, powder, and effervescent forms, and is also used intravenously in hospital settings. Its long history of use, low cost, and favorable safety profile have made it a cornerstone antioxidant.

NAC is generally well tolerated, with the most common effects being gastrointestinal, including nausea, vomiting, diarrhea, and an unpleasant sulfur odor. Higher or intravenous doses can trigger anaphylactoid reactions such as flushing, rash, and rarely bronchospasm, and it may enhance the blood-pressure-lowering effect of nitroglycerin and mildly affect platelet function. People with asthma should be cautious, and it is not a substitute for medically supervised treatment of acetaminophen overdose.

N-acetylcysteine's best-documented interaction is with nitroglycerin and other organic nitrates; controlled hemodynamic studies show NAC potentiates nitrate-induced vasodilation and helps reverse nitrate tolerance by supplying sulfhydryl groups, which can produce additive hypotension and severe headache when the two are combined. As a thiol antioxidant NAC has theoretical additive antiplatelet or bleeding effects with anticoagulants and antiplatelet drugs, though this is not firmly established clinically. In poisoning care, activated charcoal can adsorb oral NAC and reduce its availability, and NAC is the standard antidote that counteracts the hepatotoxicity of acetaminophen overdose. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

N-acetylcysteine was first developed in the 1960s as a mucolytic agent, exploiting its free thiol group to break the disulfide bonds that make mucus viscous, and it remains on the World Health Organization's list of essential medicines. In the 1970s it was found to be a life-saving antidote for acetaminophen (paracetamol) overdose, because it replenishes the hepatic glutathione depleted by the drug's toxic metabolite, and it became the standard hospital treatment for that purpose. From the 1990s onward, researchers extended interest to its antioxidant and glutamate-modulating actions, driving clinical trials across psychiatry and neurology. Today it is both an inexpensive over-the-counter supplement and a well-established hospital medicine.

NAC is regarded as one of the most versatile and well-evidenced antioxidant compounds available, prized as a direct precursor to glutathione and backed by decades of clinical use. Its reputation rests on an unusually broad and mechanistically coherent profile, buffering oxidative stress while fine-tuning glutamate signaling through the cystine-glutamate antiporter, a combination that has driven serious research into compulsive behaviors, psychiatric conditions, and neuroprotection. Users tend to describe its effects as subtle and cumulative rather than acute, in keeping with an antioxidant rather than a stimulant action. It is widely praised for being low-cost with an excellent tolerability record. Reviewers caution that, despite promising signals, results across many psychiatric indications remain mixed and not yet definitive.